外源性酮体预防性治疗偏头痛的疗效与安全性:单中心随机安慰剂对照双盲交叉试验方案
目前偏头痛预防性治疗选择有限且副作用多,能量代谢异常可能参与偏头痛病理生理。
要点
- β-羟基丁酸矿物盐诱导轻度营养性酮症(0.4-2 mmol/l)可能成为偏头痛预防新选择。
- 采用交叉设计以提高统计效能和参与率而不增加成本。
- 若证实有效安全,可为相关疾病临床试验铺路。
核心结论
- 该试验旨在证明β-羟基丁酸矿物盐在偏头痛预防中优于安慰剂且安全。
- 若证实有效安全,βHB可能为偏头痛患者提供新的预防性治疗选择。
研究设计与样本
- 单中心、随机、安慰剂对照、双盲、交叉试验。
- 患者在4周基线期后随机分配,接受βHB矿物盐或安慰剂12周,经4周洗脱期和第二个基线期后交叉接受另一种治疗12周。
关键数值与推荐
- 主要结局为干预最后4周内符合国际头痛疾病分类第3版标准的偏头痛天数较基线的平均变化,与安慰剂比较。
- 次要终点包括任何严重程度头痛天数、急性偏头痛药物使用、偏头痛强度和偏头痛及头痛相关残疾的平均变化。
- 允许合并使用曲普坦类药物(每月10天)或镇痛药(每月14天)。
- 探索性结局包括遗传分析和表达分析、氧化和亚硝化应激、血清细胞因子分析以及血βHB和葡萄糖分析(药代动力学)。
临床怎么用
- 该方案尚处试验阶段,结果未报告,暂不能用于临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently available prophylactic migraine treatment options are limited and are associated with many, often intolerable, side-effects. Various lines of research suggest that abnormalities in energy metabolism are likely to be part of migraine pathophysiology. Previously, a ketogenic diet (KD) has been reported to lead to a drastic reduction in migraine frequency. An alternative method to a strict KD is inducing a mild nutritional ketosis (0.4-2 mmol/l) with exogenous ketogenic substances. The aim of this randomised, placebo-controlled, double-blind, crossover, single-centre trial is to demonstrate safety and superiority of beta-hydroxybutyrate (βHB) in mineral salt form over placebo in migraine prevention. METHODS/DESIGN: Forty-five episodic migraineurs (5-14 migraine days/months), with or without aura, aged between 18 and 65 years, will be recruited at headache clinics in Switzerland, Germany and Austria and via Internet announcements. After a 4-week baseline period, patients will be randomly allocated to one of the two trial arms and receive either the βHB mineral salt or placebo for 12 weeks. This will be followed by a 4-week wash-out period, a subsequent second baseline period and, finally, another 12-week intervention with the alternative treatment. Co-medication with triptans (10 days per months) or analgesics (14 days per months) is permitted. The primary outcome is the mean change from baseline in the number of migraine days (meeting International Classification of Headache Disorders version 3 criteria) during the last 4 weeks of intervention compared to placebo. Secondary endpoints include mean changes in headache days of any severity, acute migraine medication use, migraine intensity and migraine and headache-related disability. Exploratory outcomes are (in addition to routine laboratory analysis) genetic profiling and expression analysis, oxidative and nitrosative stress, as well as serum cytokine analysis, and blood βHB and glucose analysis (pharmacokinetics). DISCUSSION: A crossover design was chosen as it greatly improves statistical power and participation rates, without increasing costs. To our knowledge this is the first RCT using βHB salts worldwide. If proven effective and safe, βHB might not only offer a new prophylactic treatment option for migraine patients, but might additionally pave the way for clinical trials assessing its use in related diseases. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03132233 . Registered on 27 April 2017.
引用
- Gross E, Putananickal N, Orsini AL, et al. Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial. Trials. 2019. PMID: 30654835. doi:10.1186/s13063-018-3120-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。